FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891483171> ?p ?o ?g. }

• W2891483171 endingPage "183" @default.
• W2891483171 startingPage "173" @default.
• W2891483171 abstract "β-Blockers are a heterogenous class of drugs that are no longer recommended for initial antihypertension monotherapy due to unfavorable long-term cardiovascular events observed with non-vasodilatory β-blockers. However, the comparative cardiovascular event risk between the vasodilatory β1-selective antagonist/β3 agonist nebivolol and non-vasodilatory β1-blockers, atenolol and metoprolol, is unknown. Incident nebivolol, atenolol, or metoprolol monotherapy users with hypertension were identified using US claims data (2007–2014). The first β-blocker claim on/after 1/1/2008 defined the index drug/date. Hypertensive patients without pre-index cardiovascular history were followed until index drug discontinuation (> 90 day supply gap), use of other β-blockers, or end of continuous plan enrollment. Patients were pair-wise propensity score-matched using logistic regression, adjusted for baseline demographics, Charlson Comorbidity Index score, comorbid chronic pulmonary disease, rheumatic disease, renal disease, and diabetes, and use of other antihypertensive drugs during baseline. Time to first hospital claim for a cardiovascular event was assessed via Cox proportional hazards regression, adjusted for the variables above. Inclusion criteria were met by 81,402 patients (n = 27,134 in each matched treatment cohort), with no between-cohort differences in baseline characteristics, comorbid conditions, or average follow-up duration. Atenolol and metoprolol cohorts had greater risk of hospitalization for a composite event (myocardial infarction, angina, congestive heart failure, stroke) than nebivolol users (adjusted hazard ratios [95% confidence interval] atenolol: 1.68 [1.29, 2.17]; metoprolol: 2.05 [1.59, 2.63]; P < 0.001, both). Risks of most individual cardiovascular events were also lower with nebivolol, including myocardial infarction and angina versus atenolol, and myocardial infarction, congestive heart failure, and angina versus metoprolol (P < 0.05, all). Nebivolol was associated with significantly lower risk of hospitalization due to composite cardiovascular events than atenolol or metoprolol in this large retrospective cohort study of monotherapy with three different β1-selective blockers in hypertensive patients. Allergan plc, Madison, NJ, USA." @default.
• W2891483171 created "2018-09-27" @default.
• W2891483171 creator A5014942240 @default.
• W2891483171 creator A5027534432 @default.
• W2891483171 creator A5040283324 @default.
• W2891483171 creator A5056252103 @default.
• W2891483171 creator A5072496167 @default.
• W2891483171 creator A5080066727 @default.
• W2891483171 creator A5085471610 @default.
• W2891483171 date "2018-09-06" @default.
• W2891483171 modified "2023-10-07" @default.
• W2891483171 title "Risk of Hospitalization for Cardiovascular Events with β-Blockers in Hypertensive Patients: A Retrospective Cohort Study" @default.
• W2891483171 cites W1893697707 @default.
• W2891483171 cites W1978372333 @default.
• W2891483171 cites W1992967281 @default.
• W2891483171 cites W1996667713 @default.
• W2891483171 cites W2000445173 @default.
• W2891483171 cites W2011713510 @default.
• W2891483171 cites W2016016829 @default.
• W2891483171 cites W2023140063 @default.
• W2891483171 cites W2028147850 @default.
• W2891483171 cites W2042299840 @default.
• W2891483171 cites W2054796764 @default.
• W2891483171 cites W2094326208 @default.
• W2891483171 cites W2110882681 @default.
• W2891483171 cites W2114333967 @default.
• W2891483171 cites W2126083802 @default.
• W2891483171 cites W2126125759 @default.
• W2891483171 cites W2129168200 @default.
• W2891483171 cites W2129991662 @default.
• W2891483171 cites W2133217116 @default.
• W2891483171 cites W2152660527 @default.
• W2891483171 cites W2167003284 @default.
• W2891483171 cites W2196906371 @default.
• W2891483171 cites W2314973418 @default.
• W2891483171 cites W2480651174 @default.
• W2891483171 cites W2514869850 @default.
• W2891483171 cites W2574638270 @default.
• W2891483171 cites W4211102861 @default.
• W2891483171 cites W4211261740 @default.
• W2891483171 cites W4378171839 @default.
• W2891483171 cites W910021339 @default.
• W2891483171 doi "https://doi.org/10.1007/s40119-018-0117-y" @default.
• W2891483171 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6251822" @default.
• W2891483171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30191469" @default.
• W2891483171 hasPublicationYear "2018" @default.
• W2891483171 type Work @default.
• W2891483171 sameAs 2891483171 @default.
• W2891483171 citedByCount "8" @default.
• W2891483171 countsByYear W28914831712018 @default.
• W2891483171 countsByYear W28914831712019 @default.
• W2891483171 countsByYear W28914831712021 @default.
• W2891483171 countsByYear W28914831712022 @default.
• W2891483171 countsByYear W28914831712023 @default.
• W2891483171 crossrefType "journal-article" @default.
• W2891483171 hasAuthorship W2891483171A5014942240 @default.
• W2891483171 hasAuthorship W2891483171A5027534432 @default.
• W2891483171 hasAuthorship W2891483171A5040283324 @default.
• W2891483171 hasAuthorship W2891483171A5056252103 @default.
• W2891483171 hasAuthorship W2891483171A5072496167 @default.
• W2891483171 hasAuthorship W2891483171A5080066727 @default.
• W2891483171 hasAuthorship W2891483171A5085471610 @default.
• W2891483171 hasBestOaLocation W28914831711 @default.
• W2891483171 hasConcept C126322002 @default.
• W2891483171 hasConcept C164705383 @default.
• W2891483171 hasConcept C207103383 @default.
• W2891483171 hasConcept C2776525901 @default.
• W2891483171 hasConcept C2777537511 @default.
• W2891483171 hasConcept C2778198053 @default.
• W2891483171 hasConcept C2781280847 @default.
• W2891483171 hasConcept C44249647 @default.
• W2891483171 hasConcept C500558357 @default.
• W2891483171 hasConcept C50382708 @default.
• W2891483171 hasConcept C71924100 @default.
• W2891483171 hasConcept C72563966 @default.
• W2891483171 hasConcept C84393581 @default.
• W2891483171 hasConceptScore W2891483171C126322002 @default.
• W2891483171 hasConceptScore W2891483171C164705383 @default.
• W2891483171 hasConceptScore W2891483171C207103383 @default.
• W2891483171 hasConceptScore W2891483171C2776525901 @default.
• W2891483171 hasConceptScore W2891483171C2777537511 @default.
• W2891483171 hasConceptScore W2891483171C2778198053 @default.
• W2891483171 hasConceptScore W2891483171C2781280847 @default.
• W2891483171 hasConceptScore W2891483171C44249647 @default.
• W2891483171 hasConceptScore W2891483171C500558357 @default.
• W2891483171 hasConceptScore W2891483171C50382708 @default.
• W2891483171 hasConceptScore W2891483171C71924100 @default.
• W2891483171 hasConceptScore W2891483171C72563966 @default.
• W2891483171 hasConceptScore W2891483171C84393581 @default.
• W2891483171 hasFunder F4320332585 @default.
• W2891483171 hasIssue "2" @default.
• W2891483171 hasLocation W28914831711 @default.
• W2891483171 hasLocation W28914831712 @default.
• W2891483171 hasLocation W28914831713 @default.
• W2891483171 hasLocation W28914831714 @default.
• W2891483171 hasLocation W28914831715 @default.
• W2891483171 hasOpenAccess W2891483171 @default.
• W2891483171 hasPrimaryLocation W28914831711 @default.

• next